Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

New, effective therapies are needed for pancreatic ductal adenocarcinoma. Ipilimumab can mediate an immunologic tumor regression in other histologies. This phase II trial evaluated the efficacy of Ipilimumab for advanced pancreatic cancer. Subjects were adults with locally advanced or metastatic pan...

Full description

Saved in:
Bibliographic Details
Published in:J Immunother
Main Authors: Royal, Richard E., Levy, Catherine, Turner, Keli, Mathur, Aarti, Hughes, Marybeth, Kammula, Udai S., Sherry, Richard M., Topalian, Suzanne L., Yang, James C., Lowy, Israel, Rosenberg, Steven A.
Format: Artigo
Language:Inglês
Published: 2010
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7322622/
https://ncbi.nlm.nih.gov/pubmed/20842054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0b013e3181eec14c
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items